Hemu China Biotechnology
Latest round
- Series B
Last raised
- Oct 2020
Total raised
- Undisclosed
Investors
- 3
About Hemu China Biotechnology
Established in 2016 and based in Weihai, China. Hemu China Biotechnology operates as a medical device company that focuses on minimally invasive interventional therapy for stroke and the development of related medical devices. It has 3 branch offices in Beijing, Shanghai, and Hong Kong, with 2 foreign offices in Silicon Valley and Singapore. Jicheng Wang, founder and general manager of the company, was recognized as the Shandong Province Taishan Industry Talents. Hemu China Biotechnology mainly provides neurointerventional solutions for cerebrovascular diseases such as ischemic stroke, hemorrhagic stroke, and intracranial vascular stenosis. Its products include TracLine distal access catheter, Afentta beveled suction vessels, and FlexTake intracranial thrombus extraction stent.
Who invested in Hemu China Biotechnology
3 investors across 1 round
See all investors in Hemu China Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Oct 19, 2020
Amount
Undisclosed
Investors
Questions about Hemu China Biotechnology
Who invested in Hemu China Biotechnology?
Hemu China Biotechnology has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hemu China Biotechnology raised?
Hemu China Biotechnology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hemu China Biotechnology last raise money?
Hemu China Biotechnology's most recent round on record is a Series B, in Oct 2020.
What does Hemu China Biotechnology do?
Established in 2016 and based in Weihai, China.
Where is Hemu China Biotechnology headquartered?
Hemu China Biotechnology is headquartered in Weihai, China.
Which VCs invest in companies like Hemu China Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back medical devices & equipment companies at Hemu China Biotechnology's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series B
Raising like Hemu China Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.